XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers

Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 7f98c4332e877a0a67a2bef4f13b767ed4fa2bbb
First added on: Feb 16, 2025